OncoDxRx aims to expand its exclusive liquid biopsy technology into monitoring residual disease
OncoDxRx, a California-based liquid biopsy startup, builds gene expression-powered treatment selection technology that helps clinicians identify the most suitable drugs for individual patients who are not responding to current therapies.
- (1888PressRelease) August 19, 2024 - The startup, which centers on improving treatment outcomes of non-responder patients with cancer, now aims to expand its precision medicine technology for monitoring residual disease (MRD) applications with the innovative platform called OncoMRD.
The cell-free mRNA (cfmRNA) expression technologies the company developed for drug selection are well-applied to the majority of types of solid tumors. Also, the proven knowhow acquired from developing PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) platform streamlines the building of new predictive models for OncoMRD. The PGA-to-OncoMRD expansion is happening now at OncoDxRx and will result in commercialization in 2025.
“People who are suffering from cancer and desperately need treatment right now don’t have time to wait over 10 years for a new drug,” OncoDxRx said. “Of course, it is essential to continue searching for new, better therapeutic options, but new drug development should not be the only way to improve cancer care.”
The company wants to utilize existing drugs to personalize cancer treatment regimens for individual patients. OncoDxRx’s gene expression-powered personalized drug efficacy prediction assay PGA enables oncologists to identify effective anticancer medicines that are highly likely to work for a specific patient before the doctor makes a decision.
This is how its proposed “Partner Lab Program” works: First, the oncologist collects blood samples from the patient and sends the samples to OncoDxRx’s lab in California. The company then determines the patient’s cfmRNA expression signature, and uses in silico computation analyses for pattern recognition, screening and matching to predict which drugs are most likely to be effective for the patient’s cancer. OncoDxRx provides the report to the ordering oncologist five days after receiving the sample at the lab, according to the company.
OncoDxRx is tackling a significant challenge in oncology: treating lung cancer, one of the most common cancer diagnosed in human, more effectively. As each tumor is unique, targeted treatment can be expensive, and only works for 10-20% of patients.
Each cancer patient has a different response to drugs, each lung cancer patient responds differently. Instead of a one-size-fits-all approach, OncoDxRx’s PGA technology not only increases the chances of successful treatment but can potentially reduce unnecessary costs and side effects from less effective treatments.
A milestone published study (https://www.mdpi.com/2673-7523/4/3/12) demonstrated that OncoDxRx’s PGA test correctly identified effective drugs for individual patients with relapsed lung cancer, leading to a higher complete response rate and an overall survival time longer than for those who received treatments that didn’t align with OncoDxRx’s predictions, significantly improving treatment outcomes.
There is no PGA equivalent on market today, nothing even comes closer. OncoDxRx’s exclusive edge is “the knowhow to develop and incorporate liquid biopsy gene expression models into the personalized medicine service workflow”. Developing and incorporating cfmRNA signatures into the personalized medicine service workflow requires extensive experience and expertise that other companies just don’t have.
The company is expanding its PGA and OncoMRD technologies beyond lung cancer into pancreatic and breast cancers, and will launch these tests in 2025.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam